24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Rating
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
13:43
EU approves Nvidia’s $700M acquisition of Israeli startup Run:ai
21:16
Nervio appoints Dr. Richard Vogel as US CEO
19:06
Paragon’s $900M sale in limbo as Defense Ministry steps in
15:05
Full list of Israeli high-tech funding rounds in 2024
More stories
Buzz
Most popular
Daily
Weekly
1
EU approves Nvidia’s $700M acquisition of Israeli startup Run:ai
2
Israeli tech’s top 10 funding rounds of 2024: Wiz sets another record
3
Michael Levitt Analysis: Corona Is Slowing Down, Humanity Will Survive
4
The Wiz of GenAI security? “Lasso has the potential to be a once-in-a-decade company in cyber”
5
Israel will "experience a 'baby boom' of innovation" in 2025, says RUNI Ventures
More news
Rating
5 stories about Rating
S&P to affirm Israel rating after Netanyahu guarantees firm to halt judicial overhaul
10.05.23
|
Adrian Filut
The prime minister was involved in talks with the representatives of the rating agency and promised that the judicial coup would not get passed in its original form
Fitch Downgrades Teva, Keeps Outlook at Negative
10.06.19
|
Hezi Sternlicht
Fitch pins the downgrade on the drugmaker's slow revenue growth, persisting cost challenges and downward pressure on generic drug prices, and the company's legal trouble in the U.S.
High Government Debt Countered by Strong Finances Leads Fitch to Affirm Israel's A+ Rating
26.03.19
|
Lilach Baumer
Israel scores above the median on GDP growth and human development indicators, but low on government budget deficit, government debt, and ease of doing business
Moody's Upgrades Israel's Outlook to Positive
22.07.18
|
Omri Milman
The change was based on Israel’s favorable fiscal outcomes, strong institutional framework and on its “increasingly resilient economy”
JPMorgan Downgrades Teva’s Stock to Underweight
13.11.17
|
Amarelle Wenkert
Christopher Schott, managing director at JPMorgan, said that the decision to downgrade is based on the challenges facing Teva’s generic drug unit
Please ensure Javascript is enabled for purposes of
website accessibility